An exploratory Phase IIA clinical study of ORY-1001 in combination with other agents in patients with Acute myeloid leukaemia

Trial Profile

An exploratory Phase IIA clinical study of ORY-1001 in combination with other agents in patients with Acute myeloid leukaemia

Planning
Phase of Trial: Phase II

Latest Information Update: 30 Jul 2018

At a glance

  • Drugs RG 6016 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Jul 2018 According to an Oryzon media release, the company has filed the corresponding CTA authorizations to Regulatory Agencies to carry out this trial, and will inform about its regulatory approval and the operational start thereof in due time.
    • 05 Mar 2018 According to an Oryzon media release, the company is planning to start this trial in 2H 2018.
    • 21 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top